Dr Lal PathLabs Eyes Market Share Gains: CEO Explains Growth Outlook
NDTV Profit · 05 Nov 2026 · 6 min
Management interview of Dr. Lal PathLabs Ltd (LALPATHLAB), with 4 key numbers discussed.
- Mr. Banerjee, CEO, Dr. Lal PathLabs
Dr. Lal PathLabs reported 19.4% revenue growth in H1FY27, leading to a full-year FY27 revenue growth projection in the high teens. The performance was supported by a 2% to 3% tailwind from CGHS price increases, which management expects to taper off after one more quarter. Patient volume growth stood at 9% in Q2FY27, outpacing the long-term target of 6% to 7% due to maturing network expansion and industry buoyancy. Ahead-of-plan margins in H1 will be reinvested into labs, collection infrastructure, marketing, and sales promotion.